Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Aquestive Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Aquestive Therapeutics's (NASDAQ:AQST) reported sales totaled $12.27 million. Despite a 54.33% increase in earnings, the company posted a loss of $13.22 million. In Q4, Aquestive Therapeutics brought in $11.08 million in sales but lost $28.95 million in earnings.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.